Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.

[1]  A. Turgutkaya,et al.  Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Effectivity and Adverse Events. , 2020, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[2]  F. Malavasi,et al.  CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma , 2018, Front. Immunol..

[3]  V. Suman,et al.  Update on the role of lenalidomide in patients with multiple myeloma , 2018, Therapeutic advances in hematology.

[4]  M. Dimopoulos,et al.  A Comparison of the Efficacy of Immunomodulatory‐containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta‐analysis , 2018, Clinical lymphoma, myeloma & leukemia.

[5]  S. Holstein,et al.  Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience , 2017, Drugs.

[6]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[7]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[8]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[9]  M. Boccadoro,et al.  Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.

[10]  Z. Cai,et al.  A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial , 2013, Journal of Hematology & Oncology.

[11]  M. Beksac,et al.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.

[12]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[13]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[14]  M. Boccadoro,et al.  Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. , 2012, Blood.

[15]  B. Aguado,et al.  Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma , 2011, Clinical Medicine Insights. Oncology.

[16]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[17]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[18]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[19]  Robert A Kyle,et al.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.

[20]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[21]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.